Floatz logo

Pamrevlumab

Duchenne Muscular Dystrophy

Kyntra Biomonoclonal_antibodyPhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Duchenne Muscular Dystrophy cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Aoc 1044
Avidity Biosciences, Inc.
Phase 3BB
Avi-4658
Sarepta Therapeutics, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Pamrevlumab is also rated in:

malignant pancreatic neoplasmDormant
B
Indicative ·
61 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →